| Hans-Günter Meyer-Thompson | international
Low -barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects.
Low -barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects.
Buchheit BM, Wheelock H, Lee A, Brandt K, Gregg J.
J Subst Abuse Treat. 2021 Apr 29;131:108444. doi: 10.1016/j.jsat.2021.108444. Epub ahead of print. PMID: 34098299; PMCID: PMC8081577.